Before her cancer diagnosis in early 2017, 48-year-old Caitlin Delaney, who is based in Australia, had been struggling with a troubling mix of symptoms comprising extreme fatigue, chronic sinusitis, and appetite changes including ...
Apr 23, 2026
0
4
A research team from the Department of Pathology at the University of Hong Kong's LKS Faculty of Medicine (HKUMed) has discovered that atorvastatin, a widely used cholesterol-lowering drug, could become a powerful new weapon ...
Sep 12, 2025
0
35
A research team from the School of Clinical Medicine of the LKS Faculty of Medicine of the University of Hong Kong (HKUMed) has pioneered the use of a 'dual immunotherapy' combination—nivolumab and ipilimumab (NIVO+IPI)—in ...
Jun 16, 2025
0
44
The U.S. Food and Drug Administration has approved Opdivo (nivolumab) plus Yervoy (ipilimumab) as a first-line treatment for adults with unresectable or metastatic hepatocellular carcinoma (HCC). The approval of Opdivo plus ...
Apr 16, 2025
0
17
Researchers have uncovered a promising therapeutic target for adenoid cystic carcinoma (ACC), a rare cancer of the salivary glands with few treatment options.
Mar 20, 2025
0
16
Researchers at Mount Sinai have made a breakthrough in treating a type of liver cancer called hepatocellular carcinoma (HCC). This research, led by Josep M. Llovet, MD, Ph.D., Professor of Medicine (Liver Diseases) at the ...
Jan 9, 2025
0
41
A team of researchers has uncovered the identity of off-target cells responsible for abnormal outgrowth and devised a method to eliminate them from iPS cell-derived pancreatic tissues in development for cell therapy against ...
May 13, 2024
0
62
Results of a multicenter phase II clinical trial led by the University of Chicago Medicine Comprehensive Cancer Center show that adding an immunomodulatory agent to treatment with the targeted tyrosine kinase inhibitor (TKI) ...
Sep 1, 2023
0
52
Gene therapy that induces the body to create microRNA-22 (miR-22), a naturally occurring molecule, successfully treated mice with hepatocellular carcinoma, the most common form of liver cancer.
Aug 24, 2023
0
76
While pembrolizumab is an approved treatment for patients with stage III non-small cell lung cancer (NSCLC), only some patients respond to this therapy. Treatment failure, researchers say, is often caused by differences in ...
Jul 13, 2023
0
27
